Fig. 6: Pharmacological inhibition of Suv39h1 potentiates tumor rejection by anti-PD-1 Ab. | Nature Communications

Fig. 6: Pharmacological inhibition of Suv39h1 potentiates tumor rejection by anti-PD-1 Ab.

From: CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas

Fig. 6

A Graphical representation of model system of experimental groups, including C57BL/6 mice receiving B16F10-OVA melanoma cells followed by ETP-69 oral treatment, PBS or anti-PD-1 Ab injection. B Tumor growth kinetics represented as means of one representative experiment out of 2; with n = 8 to 10 mice per group. Black arrows indicate time of initial ETP-69 or vehicle control dose administration and anti-PD-1 Ab injection. non treated n = 10, vehicle control n = 8; aPD1 n = 8; ETP-69 n = 10; ETP-69 + aPD-1 n = 10. C Tumor volumes in cm3 (day 19). non treated n = 7, vehicle control n = 7; aPD1 n = 5; ETP-69 n = 10; ETP-69 + aPD-1 n = 10. D Frequency (%) and quantification (number) of CD8 + TILs (CD45+TCRb+CD4-). nonreated n = 7, vehicle control n = 7; aPD1 n = 4; ETP-69 n = 10; ETP-69 + aPD-1 n = 10. E Frequency (%) of memory and effector CD8+ TILs from B16F10-OVA tumors. nontreated n = 7, vehicle control n = 6; aPD1 n = 4; ETP-69 n = 10; ETP-69 + aPD-1 n = 10. F Representative histogram and frequency (%) of inhibitory receptors (PD-1+, TIM-3+, LAG-3+ and 2B4+) on CD8+ TILs from B16F10-OVA tumors. nontreated n = 7, vehicle control n = 8; aPD1 n = 4; ETP-69 n = 9; ETP-69 + aPD-1 n = 10. G Pie chart of co-expression (PD-1+, TIM-3+, LAG-3+ and 2B44+) on CD8+ TILs from B16F10-OVA tumors. nontreated n = 7, vehicle control n = 8; aPD1 n = 4; ETP-69 n = 9; ETP-69 + aPD-1 n = 10. H Representative histogram and frequency (%) of GZMb+ and IFNγ+ cells among CD8+ TILs. Cells were re-stimulated in vitro with PMA and ionomycin for 4 h. nontreated n = 8, vehicle control n = 7; aPD1 n = 4; ETP-69 n = 10; ETP-69 + aPD-1 n = 10. I Representative histogram and frequency (%) of Ki67+ among CD8+ TILs from B16F10-OVA tumors. nontreated n = 7, vehicle control n = 8; aPD1 n = 4; ETP-69 n = 9; ETP-69 + aPD-1 n = 10. J Frequency (%) of TBET+EOMES+ among CD8+ PD-1+ TILs from B16F10-OVA tumors. non treated n = 7, vehicle control n = 8; aPD1 n = 4; ETP-69 n = 9; ETP-69 + aPD-1 n = 10. A representative experiment out of two is shown. p values were calculated using two-tailed Mann–Whitney test. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. In all graphs, mean ± s.e.m. are presented. See also Supplementary Fig. 6. Source data are provided as a Source Data file.

Back to article page